Literature DB >> 32920035

Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting.

Ronald Ghossein1, Justine A Barletta2, Martin Bullock3, Sarah J Johnson4, Kennichi Kakudo5, Alfred K Lam6, Mufaddal T Moonim7, David N Poller8, Giovanni Tallini9, R Michael Tuttle10, Bin Xu11, Anthony J Gill12.   

Abstract

Thyroid cancer therapy is increasingly tailored to patients' risk of recurrence and death, placing renewed importance on pathologic parameters. The International Collaboration on Cancer Reporting (ICCR), an organization promoting evidence-based, internationally agreed-upon standardized pathology data sets, is the ideal conduit for the development of a pathology reporting protocol aimed at improving the care of patients with thyroid carcinomas. An international expert panel reviewed each element of thyroid pathology reporting. Recommendations were made based on the most recent literature and expert opinion.The data set uses the most recent World Health Organization (WHO) classification for the purpose of a more clinically and prognostically relevant nomenclature. One example is the restriction of the term minimally invasive follicular carcinoma to tumors with capsular invasion only. It reinforces the already established criteria for blood vessel invasion adopted by the most recent WHO classification and Armed Forces Institute of Pathology fascicle. It emphasizes the importance of the extent of blood vessel invasion and extrathyroid extension to better stratify patients for appropriate therapy. It is the first data set that requires pathologists to use the more recently recognized prognostically powerful parameters of mitotic activity and tumor necrosis. It highlights the importance of assessing nodal disease volume in predicting the risk of recurrence.The ICCR thyroid data set provides the tools to generate a report that will guide patient treatment in a more rational manner aiming to prevent the undertreatment of threatening malignancies and spare patients with indolent tumors the morbidity of unnecessary therapy. We recommend its routine use internationally for reporting thyroid carcinoma histology. Crown
Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Data set; ICCR; Protocol; Structured report; Synoptic report; Thyroid carcinoma

Mesh:

Year:  2020        PMID: 32920035      PMCID: PMC7943644          DOI: 10.1016/j.humpath.2020.08.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  65 in total

1.  Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years.

Authors:  Yasuhiro Ito; Chisato Tomoda; Takashi Uruno; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

2.  Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome.

Authors:  Jason S Radowsky; Robin S Howard; Henry B Burch; Alexander Stojadinovic
Journal:  Thyroid       Date:  2013-09-03       Impact factor: 6.568

3.  Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings.

Authors:  W Lang; H Choritz; H Hundeshagen
Journal:  Am J Surg Pathol       Date:  1986-04       Impact factor: 6.394

4.  Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma.

Authors:  Kristine S Wong; Jochen H Lorch; Erik K Alexander; Ellen Marqusee; Nancy L Cho; Matthew A Nehs; Gerard M Doherty; Justine A Barletta
Journal:  Thyroid       Date:  2019-09       Impact factor: 6.568

5.  Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival.

Authors:  Luc G T Morris; Ashok R Shaha; R Michael Tuttle; Andrew G Sikora; Ian Ganly
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

6.  Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma.

Authors:  L A Akslen; V A LiVolsi
Journal:  Cancer       Date:  2000-04-15       Impact factor: 6.860

7.  Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.

Authors:  Ronald A Ghossein; David H Hiltzik; Diane L Carlson; Snehal Patel; Ashok Shaha; Jatin P Shah; Robert M Tuttle; Bhuvanesh Singh
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

8.  Extent of Extrathyroidal Extension as a Significant Predictor of Nodal Metastasis and Extranodal Extension in Patients with Papillary Thyroid Carcinoma.

Authors:  Ji Won Kim; Jong-Lyel Roh; Gyungyup Gong; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Ann Surg Oncol       Date:  2016-09-21       Impact factor: 5.344

9.  Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.

Authors:  Michael Rivera; Ronald A Ghossein; Heiko Schoder; Daniel Gomez; Steven M Larson; R Michael Tuttle
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

Review 10.  The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.

Authors:  Gregory W Randolph; Quan-Yang Duh; Keith S Heller; Virginia A LiVolsi; Susan J Mandel; David L Steward; Ralph P Tufano; R Michael Tuttle
Journal:  Thyroid       Date:  2012-10-19       Impact factor: 6.568

View more
  1 in total

1.  Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression.

Authors:  Bozidar Kovacevic; Dragana Vucevic; Snezana Cerovic; Catarina Eloy
Journal:  Head Neck Pathol       Date:  2021-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.